Describing a problem with NO solution is a fireable offense in any business!
Gut microbiota-derived tryptophan metabolites and inflammatory factors enhance prediction of early neurological deterioration after intravenous thrombolysis in stroke patients: a comparative model study
Abstract
Early neurological deterioration (END) after stroke thrombolysis predicts poor outcomes. This study developed predictive nomograms that incorporate gut-derived tryptophan metabolites and inflammatory markers to predict END.
Methods:
We evaluated demographic, clinical, and laboratory variables, including gut-derived tryptophan metabolites and inflammatory markers. A multivariable logistic regression model was developed to predict END and presented as a nomogram. Model performance was assessed using variance inflation factors, ROC analysis, calibration curves, and decision curve analysis. Net Reclassification Improvement and Integrated Discrimination Improvement were used to compare models.
Results:
In this study, END occurred in 11.26% of stroke patients and was independently associated with systolic blood pressure (SBP), fasting blood glucose, and serum levels of indole-3-propionic acid (IPA), indole-3-lactic acid (ILA), and interferon γ (IFN γ). Two nomogram models were developed to predict END: one based on conventional risk factors (SBP and glucose) and another incorporating emerging biomarkers (SBP, glucose, ILA, IPA, and IFN γ). The models achieved AUC scores of 0.719 (95% CI 0.658–0.780) and 0.909 (95% CI 0.879–0.939), respectively. Comparing the models showed a categorical Net Reclassification Improvement of 0.601 (p = 0.000) and an Integrated Discrimination Improvement of 0.197 (p = 0.000).
Conclusion:
Incorporating gut microbiota-derived tryptophan metabolites and inflammatory factors improves prediction of END among thrombolyzed stroke patients.
No comments:
Post a Comment